Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014.[1] The company is headquartered in Tokyo.Osamu Nagayama is the current representative director and chairman.Tatsuro Kosaka is the current representative director, president and CEO.
History
Timeline
This is a timeline of important events of Chugai Pharmaceutical.[2]
1925: Juzo Ueno founded Chugai Shinyaku Co. Ltd. and started importing and selling medicines
1927: Start of the first own production
1930: Salobrocanon, an analgesic (pain reliever ) and antipyretic, is launched
1937: Calcium bromide production begins
1943: Name changed to Chugai Pharmaceutical Co., Ltd. based in Tokyo
1944: Acquisition of Matsunaga Pharmaceutical Ltd. and construction of a plant in Matsunaga
1945: The headquarters, the factories in Ikebukuro, Sakai and Takada were destroyed in World War II, the headquarters were relocated to Takada, the factory in Takada was rebuilt
1946: Construction of the plant in Kamagiishi
1951: Guronsan, a drug to detoxify and restore liver function, is launched
1952: Varsan, a perspiration insecticide, is launched
1955: Chugai became a public company.
1956: The stock is listed on the Tokyo Stock Exchange
1957: Construction of the Ukima plant
1960: Establishment of a research center (Takada Research Laboratory, Tokyo)
1967: Foundation of Fukushima Kasai Co Ltd.
1961 – Developed patents for synthesis of vitamin A
1969: The name of Fukushima Kasai Co Ltd. is changed to Eiko Kasei Co Ltd., after the merger of Fukushima Kasai Co Ltd. and Fukuma Kasau Co. Ltd.
1971: Construction of the factory in Fujieda
1975: Picibanil, a cancer drug, is launched
1982: Opening of a branch in New York
1986: Opening of a branch in London
1989: Acquisition of Gen-Probe Incorporated (USA)
1990: Epogin launched
1995 – Released acute promyelocytic sphere of leukemia drug treatment Vesanoid
2000 – Released antiemetic drug Kytril, developed to combat the side effects of chemotherapy
2001 – Produced anti-influenza virusTamiflu (Roche)
2002: Start of the alliance with Roche
2003: Xeloda, a cancer drug, is launched
2005: Actemra launched
2007: Copegus, an antiviral, Avastin, a cancer drug, and Tarceva, a cancer drug launched
2011 – Produced Actemra, a human IL-6 receptor monoclonal antibody for rheumatoid arthritis
2014: Launch of Kadcyla, a cancer drug, Chugai Pharma China Co Ltd. founded
2015 – In March the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of US$205 million.[3]
2016: Cooperation between Osaka University and Chugai
2018: Tecentriq, a cancer drug, is launched
2020 – FDA approved satralizumab (Enspryng) for treatment of the orphan diseaseneuromyelitis optica[4]
See also
Biotech and pharmaceutical companies in the New York metropolitan area
